Galapagos (ADR) (GLPG)
Belgian biotech shifting from cell therapy toward partnered immunology and oncology assets.
Galapagos NV (GLPG) Q1 2026 Earnings Call Transcript
Galapagos NV (GLPG) Q1 2026 Earnings Call Transcript
Galapagos' Shareholders Adopt All Resolutions Proposed by the Board of Directors at the Annual and Extraordinary Shareholders' Meetings 2026
Mechelen, Belgium; April 28, 2026, 22:01 CET — Galapagos NV (Euronext & NASDAQ: GLPG) today announces that all resolutions proposed at the Company's Annual and Extraordinary Shareholders' Meetings (AGM and EGM) held on 28 April 2026 were approved.
Galapagos (NASDAQ:GLPG) Stock Crosses Below 200 Day Moving Average – Time to Sell?
Galapagos NV (NASDAQ: GLPG - Get Free Report)'s share price crossed below its 200-day moving average during trading on Tuesday. The stock has a 200-day moving average of $32.63 and traded as low as $28.27. Galapagos shares last traded at $28.93, with a volume of 249,516 shares changing hands. Analysts Set New Price Targets Several
Galapagos en Gilead gaan definitieve overeenkomst aan over samenwerking om een first-in-class T-cel-engagerprogramma voor auto-immuunziekten verder te ontwikkelen
De nieuwe samenwerkingsstructuur levert aanzienlijk verbeterde financiële voorwaarden en flexibiliteit voor Galapagos op Na deze transactie blijft de Vennootschap over het grootste deel van haar liquide middelen beschikken voor bijkomende strategische transacties en andere prioriteiten van kapitaalallocatie Kans om met gamgertamig een potentieel first-in-class and best-in-class T-cell-engager in auto-immuunziekten te ontwikkelen Management houdt vandaag, 31 maart 2026, om 14:00 CET / 08:00 ET een conference call Mechelen, België; 31 maart 2026, 07:30 CET; gereglementeerde informatie - Aankondiging overeenkomstig artikel 7:97, §4/1 van het WVV - Galapagos NV (Euronext and NASDAQ: GLPG) ("Galapagos" of de "Vennootschap") heeft vandaag bekendgemaakt dat het een definitieve overeenkomst heeft gesloten (de "Kaderovereenkomst") met Gilead Sciences, Inc.
Galapagos kondigt de voordracht aan van Gino Santini tot lid van de Raad van Bestuur
De Raad van Bestuur is voornemens de heer Santini te benoemen tot Voorzitter, als opvolger van Jérôme Contamine, onder voorbehoud van zijn benoeming door aandeelhouders De heer Santini zal uitgebreide ervaring op het gebied van corporate governance, bedrijfsontwikkeling en leiderschap in de sector toevoegen aan de Raad van Bestuur Mechelen, België; 26 maart, 2026, 21:02 CET - Galapagos NV (Euronext and NASDAQ: GLPG), heeft vandaag bekendgemaakt dat Gino Santini is voorgedragen als Niet-Uitvoerend Onafhankelijk Bestuurder, met de bedoeling hem te benoemen tot Voorzitter van de Raad van Bestuur, onder voorbehoud van goedkeuring door aandeelhouders tijdens de Gewone (jaarlijkse) Algemene Vergadering (GAV) op 28 april 2026.
Galapagos Announces Nomination of Gino Santini to its Board of Directors
Subject to his election by shareholders, the Board intends to appoint Mr. Santini as Chair, succeeding Jérôme Contamine
Galapagos publiceert 2025 jaarverslag en kondigt de Gewone (jaarlijkse) en Buitengewone Algemene Vergaderingen aan
Mechelen, België; 26 maart, 2026, 21:01 CET; gereglementeerde informatie - Galapagos NV (Euronext and NASDAQ: GLPG) heeft vandaag haar jaarverslag over het boekjaar 2025 gepubliceerd en aangekondigd dat haar Gewone (jaarlijkse) Algemene Vergadering (GAV) en een Buitengewone Algemene Vergadering (BAV) achtereenvolgens zullen plaatsvinden op dinsdag 28 april 2026 om 14. 00 uur en 15. 00 uur te Schaliënhoevedreef 20T, 2800 Mechelen, België. Het jaarverslag over het boekjaar 2025, inclusief een overzicht van de cijfers en de prestaties, is online beschikbaar op https://www.
Galapagos and Gilead in Advanced Discussions to Collaborate on Advancing First in Class T Cell Engager Program for Autoimmune Diseases
Galapagos intends to enter into a strategic collaboration with Gilead following Gilead's acquisition of Ouro Medicines
Galapagos Receives Transparency Notification from Bank of America
Mechelen, Belgium ; March 117, 2026, 22:01 CET; regulated information – Galapagos NV (Euronext & NASDAQ: GLPG) received a transparency notification from Bank of America.
Galapagos Receives Transparency Notifications from Bank of America
Mechelen, Belgium ; March 10, 2026, 22:01 CET; regulated information – Galapagos NV (Euronext & NASDAQ: GLPG) received transparency notifications from Bank of America.
Galapagos Creates New Subscription Right Plan
Mechelen, Belgium; March 6, 2026, 22.01 CET; regulated information – Galapagos NV (Euronext & NASDAQ: GLPG) announced today that its Board of Directors created 1,750,000 subscription rights under a new subscription right plan.
Galapagos Appoints Tania Philipp as Chief Human Resources Officer
Seasoned Life Sciences Executive Joins Galapagos with Strong Track Record in Change Management Mechelen, Belgium; March 5, 2026, 22:01 CET — Galapagos NV (Euronext & NASDAQ: GLPG) today announced the appointment of Tania Philipp as Chief Human Resources Officer (CHRO), effective March 4, 2026. Ms. Philipp will also join the Management Committee.
Galapagos Receives Transparency Notifications from Bank of America
Mechelen, Belgium ; March 4, 2026, 22:01 CET; regulated information – Galapagos NV (Euronext & NASDAQ: GLPG) received transparency notifications from Bank of America.
Galapagos NV (GLPG) Q4 2025 Earnings Call Transcript
Galapagos NV (GLPG) Q4 2025 Earnings Call Transcript
Galapagos Reports Full Year 2025 Financial Results and Provides Fourth Quarter Business Update
Mechelen, Belgium; February 23, 2026, 22:01 CET; regulated information – Galapagos NV (Euronext & NASDAQ: GLPG) today reported its financial results for the full year 2025 and provided an update on the fourth quarter 2025 and its year-to-date performance.
Galapagos Receives Transparency Notification from Bank of America
Mechelen, Belgium ; February 16, 2026, 22:01 CET; regulated information – Galapagos NV (Euronext & NASDAQ: GLPG) received a transparency notification from Bank of America.
Galapagos Announces Board Decision to Initiate Wind-Down of Cell Therapy Activities
Mechelen, Belgium ; January 5, 2026, 22:01 CET; Galapagos NV (Euronext & NASDAQ: GLPG) today announced that the works council consultation process regarding the wind-down of cell therapy activities has been completed and its Board of Directors has decided to initiate the wind-down of the Company's cell therapy activities.
Galapagos: Pivoting From Clinical Risk To Strategic Capital Allocation
Galapagos now presents a deep value opportunity, underpinned by a €3B cash reserve and a decisive shift to capital allocation discipline. GLPG's restructuring—discontinuing cell therapy, slashing headcount, and targeting cash flow neutrality by YE2026—positions it as a streamlined M&A platform. Management's M&A-focused pedigree, led by ex-AbbVie dealmakers, signals a pivot from pipeline reliance to transformative business development using its cash war chest.
Galapagos Presented New ATALANTA-1 Cell Therapy Data in MCL at ASH 2025
High complete response rates and minimal residual disease (MRD) negativity, with durable responses, in high-risk mantle cell lymphoma (MCL) with GLPG5101, a fresh, early memory-enriched CAR T-cell therapy with a 7-day vein-to-vein time
Galapagos Receives Transparency Notifications from Bank of America
Mechelen, Belgium ; November 26, 2025, 07:30 CET; regulated information – Galapagos NV (Euronext & NASDAQ: GLPG) received transparency notifications from Bank of America.